Table 2 Univariate Cox regression analyses for overall survival and relapse-free survival in ovarian carcinomas

Age, y, ≥ 60 (vs < 60)

33/104

2.686 (1.535-4.698)

<0.001

2.157 (1.299-3.582)

0.003

Stage, III & IV (vs I & II)

52/104

3.579 (1.917-6.681)

<0.001

3.930 (2.245-6.878)

<0.001

Tumor size, cm, > 10 (vs ≤ 10)

36/104

0.524 (0.274-1.004)

0.051

0.649 (0.375-1.125)

0.123

LN metastasis, presence (vs absence)

20/104

1.568 (0.831-2.959)

0.165

1.889 (1.076-3.314)

0.027

Ascites, presence (vs absence)

33/104

1.997 (1.140-3.498)

0.016

1.854 (1.116-3.077)

0.017

Bilaterality, bilateral (vs unilateral)

45/104

1.647 (0.943-2.876)

0.080

1.995 (1.204-3.303)

0.007

CA19-9, elevated (vs normal)

17/83

0.753 (0.314-1.806)

0.525

0.811 (0.379-1.733)

0.588

CA125, elevated (vs normal)

75/93

4.451 (1.376-14.393)

0.013

4.458 (1.609-12.351)

0.004

Histologic grade, high (vs low)

77/104

3.762 (1.491-9.496)

0.005

3.794 (1.719-8.374)

<0.001

DBC1, positive (vs negative)

66/104

3.474 (1.684-7.166)

<0.001

3.007 (1.624-5.567)

<0.001

BRCA1, positive (vs negative)

46/104

2.263 (1.287-3.979)

0.005

2.254 (1.359-3.739)

0.002

Age, y, ≥ 60 (vs < 60)

30/75

2.601 (1.411-4.796)

0.002

1.926 (1.116-3.323)

0.019

Stage, III & IV (vs I & II)

46/75

2.263 (1.131-4.528)

0.021

2.809 (1.485-5.312)

0.001

Tumor size, cm, > 10 (vs ≤ 10)

19/75

0.625 (0.289-1.352)

0.233

0.817 (0.436-1.532)

0.529

LN metastasis, presence (vs absence)

19/75

1.200 (0.613-2.349)

0.595

1.502 (0.831-2.714)

0.178

Ascites, presence (vs absence)

30/75

1.793 (0.977-3.291)

0.060

1.645 (0.953-2.839)

0.074

Bilaterality, bilateral (vs unilateral)

41/75

1.200 (0.647-2.224)

0.563

1.423 (0.813-2.492)

0.217

CA19-9, elevated (vs normal)

8/58

0.679 (0.206-2.236)

0.524

1.086 (0.425-2.773)

0.863

CA125, elevated (vs normal)

61/68

2.898 (0.697-12.056)

0.144

2.152 (0.668-6.931)

0.199

Histologic grade, high (vs low)

63/75

4.401 (1.061-18.260)

0.041

4.341 (1.347-13.990)

0.014

DBC1, positive (vs negative)

54/75

4.277 (1.674-10.926)

0.002

2.811 (1.363-5.794)

0.005

BRCA1, positive (vs negative)

36/75

1.861 (1.007-3.438)

0.047

1.792 (1.032-3.110)

0.038

Age, y, ≥ 60 (vs < 60)

27/63

2.090 (1.119-3.900)

0.021

1.591 (0.907-2.791)

0.105

Stage, III & IV (vs I & II)

38/63

2.188 (1.080-4.434)

0.030

2.811 (1.464-5.399)

0.002

Tumor size, cm, > 10 (vs ≤ 10)

15/63

0.736 (0.339-1.599)

0.439

0.860 (0.448-1.651)

0.650

LN metastasis, presence (vs absence)

15/63

1.520 (0.766-3.017)

0.232

1.841 (0.992-3.417)

0.053

Ascites, presence (vs absence)

26/63

1.395 (0.749-2.598)

0.294

1.340 (0.764-2.351)

0.308

Bilaterality, bilateral (vs unilateral)

36/63

1.300 (0.683-2.475)

0.424

1.452 (0.809--2.603)

0.211

CA19-9, elevated (vs normal)

6/49

0.726 (0.220-2.403)

0.600

1.344 (0.521-3.467)

0.541

CA125, elevated (vs normal)

53/58

2.220 (0.531-9.276)

0.275

1.443 (0.446-4.672)

0.540

DBC1, positive (vs negative)

50/63

4.031 (1.427-11.382)

0.008

2.540 (1.135-5.684)

0.023

BRCA1, positive (vs negative)

32/63

2.010 (1.063-3.803)

0.032

1.719 (0.973-3.038)

0.062